These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 39011717

  • 21. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR, Bakris GL, Gross C, Mayo MR, Garza D, Stasiv Y, Yuan J, Berman L, Williams GH.
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [Abstract] [Full Text] [Related]

  • 22. Combined blockade of renin-angiotensin-aldosterone system reduced all-cause but not cardiovascular mortality in dialysis patients: A mediation analysis and systematic review.
    Li SM, He WB, Chen J, Cai QQ, Huang FF, Zhang K, Wang JF, Liu X, Huang H.
    Atherosclerosis; 2018 Feb; 269():35-41. PubMed ID: 29258005
    [Abstract] [Full Text] [Related]

  • 23. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?
    Sarafidis PA, Ruilope LM.
    Kidney Int; 2014 Mar; 85(3):536-46. PubMed ID: 24048382
    [Abstract] [Full Text] [Related]

  • 24. The Use of Renin-Angiotensin System Inhibitors in Patients With Chronic Kidney Disease.
    Leon SJ, Tangri N.
    Can J Cardiol; 2019 Sep; 35(9):1220-1227. PubMed ID: 31472818
    [Abstract] [Full Text] [Related]

  • 25. The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through 'stacking' of drugs from different classes.
    Bell DSH, Jerkins T.
    Diabetes Obes Metab; 2024 Jun; 26(6):2046-2053. PubMed ID: 38516874
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia.
    Hsu TW, Liu JS, Hung SC, Kuo KL, Chang YK, Chen YC, Hsu CC, Tarng DC.
    JAMA Intern Med; 2014 Mar; 174(3):347-54. PubMed ID: 24343093
    [Abstract] [Full Text] [Related]

  • 28. Renin-angiotensin-aldosterone system inhibitors in heart failure.
    Shearer F, Lang CC, Struthers AD.
    Clin Pharmacol Ther; 2013 Oct; 94(4):459-67. PubMed ID: 23852393
    [Abstract] [Full Text] [Related]

  • 29. Effect of SGLT2 Inhibitors on Discontinuation of Renin-angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials.
    Fletcher RA, Jongs N, Chertow GM, McMurray JJV, Arnott C, Jardine MJ, Mahaffey KW, Perkovic V, Rockenschaub P, Rossing P, Correa-Rotter R, Toto RD, Vaduganathan M, Wheeler DC, Heerspink HJL, Neuen BL.
    J Am Soc Nephrol; 2023 Dec 01; 34(12):1965-1975. PubMed ID: 37876229
    [Abstract] [Full Text] [Related]

  • 30. Blockade of Renin-Angiotensin-Aldosterone System in Elderly Patients with Heart Failure and Chronic Kidney Disease: Results of a Single-Center, Observational Cohort Study.
    Martínez-Milla J, García MC, Urquía MT, Castillo ML, Arbiol AD, Monteagudo ALR, Mariscal MLM, Figuero SB, Franco-Pelaéz JA, Tuñón J.
    Drugs Aging; 2019 Dec 01; 36(12):1123-1131. PubMed ID: 31493202
    [Abstract] [Full Text] [Related]

  • 31. Mineralcorticoid receptor blockers in chronic kidney disease.
    Erraez S, López-Mesa M, Gómez-Fernández P.
    Nefrologia (Engl Ed); 2021 Dec 01; 41(3):258-275. PubMed ID: 36166243
    [Abstract] [Full Text] [Related]

  • 32. RAAS inhibition and renal protection.
    Leoncini G, Viazzi F, Pontremoli R.
    Curr Pharm Des; 2012 Dec 01; 18(7):971-80. PubMed ID: 22283776
    [Abstract] [Full Text] [Related]

  • 33. A mechanism for mineralocortcoid participation in renal disease and heart failure.
    Re RN.
    J Am Soc Hypertens; 2015 Aug 01; 9(8):586-91. PubMed ID: 26101172
    [Abstract] [Full Text] [Related]

  • 34. Dual renin-angiotensin system blockade for nephroprotection.
    Ruggenenti P.
    Nephrol Ther; 2017 Apr 01; 13 Suppl 1():S43-S45. PubMed ID: 28577742
    [Abstract] [Full Text] [Related]

  • 35. Detrimental effect of renin-angiotensin blockade on progression of chronic kidney disease at later stages: A matter of dosage adjustment?
    Caravaca-Fontán F, Valladares J, Díaz-Campillejo R, Barroso S, Luna E, Caravaca F.
    Nefrologia (Engl Ed); 2020 Apr 01; 40(1):38-45. PubMed ID: 31196659
    [Abstract] [Full Text] [Related]

  • 36. Preserving Kidney Function Instead of Replacing It.
    Kliger AS, Brosius FC, Diabetic Kidney Disease Task Force of the American Society of Nephrology.
    Clin J Am Soc Nephrol; 2020 Jan 07; 15(1):129-131. PubMed ID: 31594804
    [No Abstract] [Full Text] [Related]

  • 37. Benefit of Renin Angiotensin Aldosterone Blockade in Kidney Transplant Recipients: Is the Verdict in or Still to Be Answered?
    Sawinski D, Mottl AK.
    Clin J Am Soc Nephrol; 2024 Jun 01; 19(6):691-693. PubMed ID: 38758607
    [No Abstract] [Full Text] [Related]

  • 38. Aldosterone blockade in CKD: emphasis on pharmacology.
    Schwenk MH, Hirsch JS, Bomback AS.
    Adv Chronic Kidney Dis; 2015 Mar 01; 22(2):123-32. PubMed ID: 25704349
    [Abstract] [Full Text] [Related]

  • 39. The renin-angiotensin-aldosterone system and heart failure.
    Sayer G, Bhat G.
    Cardiol Clin; 2014 Feb 01; 32(1):21-32, vii. PubMed ID: 24286576
    [Abstract] [Full Text] [Related]

  • 40. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.
    Am J Kidney Dis; 2008 Sep 01; 52(3):486-93. PubMed ID: 18423812
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.